Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1109 studies found for:    "Hodgkin Disease"
Show Display Options
Rank Status Study
21 Recruiting Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
Condition: Hodgkin's Disease
Intervention:
22 Completed Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Conditions: Hodgkin's Disease;   Breast Cancer
Intervention: Drug: Tamoxifen
23 Withdrawn Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Conditions: Hodgkin's Disease;   Lymphoma
Intervention: Drug: Alemtuzumab (Campath-1H)
24 Completed Quality of Life Among Survivors of Hodgkin Lymphoma
Condition: Hodgkin's Disease
Intervention: Behavioral: Quality of Life Questionaires
25 Active, not recruiting Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
Condition: Hodgkin Disease
Interventions: Drug: Nivolumab;   Drug: Doxorubicin;   Drug: Vinblastine;   Drug: Dacarbazine
26 Active, not recruiting Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide
27 Completed Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients
Conditions: Hodgkin Lymphoma;   Hodgkin Disease
Intervention: Drug: triptorelin
28 Recruiting Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab Vedotin;   Drug: Etoposide;   Drug: Carboplatine;   Drug: Ifosfamide
29 Terminated Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: Bortezomib;   Drug: Dexamethasone
30 Completed Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide
31 Recruiting A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response
Condition: Hodgkin Disease
Interventions: Biological: Nivolumab;   Biological: brentuximab vedotin;   Biological: bendamustine
32 Completed Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
Conditions: Breast Cancer;   Hodgkin's Disease
Interventions: Procedure: breast MRI;   Procedure: Mammogram
33 Completed Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
Condition: Hodgkin's Disease
Interventions: Drug: Prednisone;   Drug: Vinblastine;   Drug: Doxorubicin (Adriamycin);   Drug: Gemcitabine
34 Completed Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide (Revlimid®)
35 Completed Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic
Condition: Hodgkin's Disease
Intervention: Other: Collection of blood specimen
36 Recruiting A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
37 Active, not recruiting
Has Results
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine
38 Unknown  Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Disease
Intervention: Drug: I-131 Tositumomab therapeutic regimen
39 Recruiting Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Condition: Hodgkin Disease
Interventions: Drug: ABVE-PC;   Drug: DECA
40 Active, not recruiting
Has Results
Therapy for Pediatric Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: 12 Week Stanford V Chemotherapy;   Drug: 4 cycles of VAMP chemotherapy;   Drug: 2 alternating cycles of VAMP/COP chemotherapy;   Drug: 3 alternating cycles of VAMP/COP chemotherapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.